Astrazeneca Plc $AZN Stake Reduced by Keybank National Association OH

Keybank National Association OH trimmed its holdings in Astrazeneca Plc (NYSE:AZN) by 25.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,168 shares of the company’s stock after selling 13,871 shares during the quarter. Keybank National Association OH’s holdings in Astrazeneca were worth $7,922,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in AZN. Brighton Jones LLC increased its holdings in shares of Astrazeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after buying an additional 2,789 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Astrazeneca by 45.3% in the 1st quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after acquiring an additional 11,690 shares during the last quarter. Amundi raised its position in shares of Astrazeneca by 54.4% during the second quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after purchasing an additional 3,618 shares during the period. Jump Financial LLC raised its position in shares of Astrazeneca by 898.4% during the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after purchasing an additional 30,125 shares during the period. Finally, Daiwa Securities Group Inc. lifted its holdings in shares of Astrazeneca by 1.2% during the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock valued at $3,259,000 after purchasing an additional 559 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. UBS Group reissued a “buy” rating on shares of Astrazeneca in a research note on Friday, April 10th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Astrazeneca in a research note on Tuesday, June 30th. Barclays reiterated a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Fourteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Trading Down 0.1%

Astrazeneca stock opened at $194.96 on Friday. Astrazeneca Plc has a 12 month low of $137.23 and a 12 month high of $212.71. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock has a market cap of $302.36 billion, a P/E ratio of 29.27, a P/E/G ratio of 1.58 and a beta of 0.24. The company’s fifty day simple moving average is $183.96 and its 200-day simple moving average is $188.09.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. The business had revenue of $15.29 billion during the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%. As a group, sell-side analysts forecast that Astrazeneca Plc will post 10.28 EPS for the current fiscal year.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.